Cabaletta Bio Stock Analysis
CABA Stock | USD 3.51 0.05 1.40% |
Cabaletta Bio is undervalued with Real Value of 8.8 and Target Price of 25.29. The main objective of Cabaletta Bio stock analysis is to determine its intrinsic value, which is an estimate of what Cabaletta Bio is worth, separate from its market price. There are two main types of Cabaletta Bio's stock analysis: fundamental analysis and technical analysis.
The Cabaletta Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cabaletta Bio's ongoing operational relationships across important fundamental and technical indicators.
Cabaletta |
Cabaletta Stock Analysis Notes
About 97.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.16. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cabaletta Bio recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Cabaletta Bio please contact the company at 267 759 3100 or go to https://www.cabalettabio.com.Cabaletta Bio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cabaletta Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cabaletta Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cabaletta Bio generated a negative expected return over the last 90 days | |
Cabaletta Bio has high historical volatility and very poor performance | |
Net Loss for the year was (67.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Cabaletta Bio currently holds about 96.81 M in cash with (53.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34. | |
Cabaletta Bio has a poor financial position based on the latest SEC disclosures | |
Over 97.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from gurufocus.com: Cabaletta Bio to Participate in Upcoming Investor Conferences in December |
Cabaletta Bio Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cabaletta Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Cabaletta Largest EPS Surprises
Earnings surprises can significantly impact Cabaletta Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-03-16 | 2020-12-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-08-06 | 2020-06-30 | -0.39 | -0.35 | 0.04 | 10 | ||
2022-08-11 | 2022-06-30 | -0.5 | -0.45 | 0.05 | 10 |
Cabaletta Bio Environmental, Social, and Governance (ESG) Scores
Cabaletta Bio's ESG score is a quantitative measure that evaluates Cabaletta Bio's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cabaletta Bio's operations that may have significant financial implications and affect Cabaletta Bio's stock price as well as guide investors towards more socially responsible investments.
Cabaletta Stock Institutional Investors
Shares | Commodore Capital Lp | 2024-09-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | State Street Corp | 2024-09-30 | 896.1 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 828.8 K | Point72 Asset Management, L.p. | 2024-09-30 | 667.3 K | Victory Capital Management Inc. | 2024-09-30 | 629.1 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 573.2 K | T. Rowe Price Associates, Inc. | 2024-09-30 | 552.8 K | Integral Health Asset Management, Llc | 2024-09-30 | 450 K | Jennison Associates Llc | 2024-09-30 | 5.6 M | Blackrock Inc | 2024-06-30 | 4.8 M |
Cabaletta Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 174 M.Cabaletta Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.27) | (0.28) | |
Return On Capital Employed | (0.31) | (0.30) | |
Return On Assets | (0.27) | (0.28) | |
Return On Equity | (0.29) | (0.27) |
Management Efficiency
Cabaletta Bio has return on total asset (ROA) of (0.3113) % which means that it has lost $0.3113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4816) %, meaning that it created substantial loss on money invested by shareholders. Cabaletta Bio's management efficiency ratios could be used to measure how well Cabaletta Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.28. The current year's Return On Capital Employed is expected to grow to -0.3. At present, Cabaletta Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 9.6 M, whereas Net Tangible Assets are forecasted to decline to about 84 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.77 | 6.06 | |
Tangible Book Value Per Share | 5.77 | 6.06 | |
Enterprise Value Over EBITDA | (10.12) | (9.62) | |
Price Book Value Ratio | 3.94 | 4.13 | |
Enterprise Value Multiple | (10.12) | (9.62) | |
Price Fair Value | 3.94 | 4.13 | |
Enterprise Value | 224.2 M | 153.2 M |
Cabaletta Bio's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 2.419 | Return On Assets (0.31) | Return On Equity (0.48) |
Technical Drivers
As of the 4th of December, Cabaletta Bio shows the mean deviation of 6.32, and Risk Adjusted Performance of (0.02). Cabaletta Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cabaletta Bio Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cabaletta Bio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cabaletta Bio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cabaletta Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cabaletta Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cabaletta Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cabaletta Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cabaletta Bio Outstanding Bonds
Cabaletta Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cabaletta Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cabaletta bonds can be classified according to their maturity, which is the date when Cabaletta Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
CA INC 47 Corp BondUS12673PAJ49 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
CW Senior Financing Corp BondUS12674TAA43 | View | |
HEXWIN 5375 31 OCT 26 Corp BondUS12674CAA18 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cabaletta Bio Predictive Daily Indicators
Cabaletta Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cabaletta Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 544834.0 | |||
Daily Balance Of Power | (0.11) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 3.56 | |||
Day Typical Price | 3.54 | |||
Price Action Indicator | (0.07) | |||
Period Momentum Indicator | (0.05) |
Cabaletta Bio Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 17th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 30th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 22nd of August 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Cabaletta Bio Forecast Models
Cabaletta Bio's time-series forecasting models are one of many Cabaletta Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cabaletta Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cabaletta Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cabaletta Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cabaletta shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cabaletta Bio. By using and applying Cabaletta Stock analysis, traders can create a robust methodology for identifying Cabaletta entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Cabaletta Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cabaletta analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cabaletta analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
25.29 | Strong Buy | 12 | Odds |
Most Cabaletta analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cabaletta stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cabaletta Bio, talking to its executives and customers, or listening to Cabaletta conference calls.
Cabaletta Stock Analysis Indicators
Cabaletta Bio stock analysis indicators help investors evaluate how Cabaletta Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cabaletta Bio shares will generate the highest return on investment. By understating and applying Cabaletta Bio stock analysis, traders can identify Cabaletta Bio position entry and exit signals to maximize returns.
Begin Period Cash Flow | 81.6 M | |
Common Stock Shares Outstanding | 40.9 M | |
Total Stockholder Equity | 236.2 M | |
Property Plant And Equipment Net | 7.5 M | |
Cash And Short Term Investments | 241.2 M | |
Cash | 193.2 M | |
Accounts Payable | 4.5 M | |
Net Debt | -188.2 M | |
50 Day M A | 3.9028 | |
Total Current Liabilities | 16 M | |
Other Operating Expenses | 74.7 M | |
Non Current Assets Total | 9.2 M | |
Non Currrent Assets Other | 1.7 M | |
Stock Based Compensation | 11.3 M |
Complementary Tools for Cabaletta Stock analysis
When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |